Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Assets (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Assets readings, the most recent being $881.1 million for Q4 2025.

  • On a quarterly basis, Assets fell 8.94% to $881.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $881.1 million, a 8.94% decrease, with the full-year FY2025 number at $881.1 million, down 8.94% from a year prior.
  • Assets hit $881.1 million in Q4 2025 for Tandem Diabetes Care, up from $874.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.1 billion in Q4 2022 to a low of $754.3 million in Q1 2021.
  • Median Assets over the past 5 years was $940.5 million (2023), compared with a mean of $930.4 million.
  • Biggest five-year swings in Assets: skyrocketed 119.7% in 2021 and later fell 10.27% in 2023.
  • Tandem Diabetes Care's Assets stood at $905.1 million in 2021, then increased by 16.31% to $1.1 billion in 2022, then fell by 9.51% to $952.7 million in 2023, then rose by 1.57% to $967.7 million in 2024, then decreased by 8.94% to $881.1 million in 2025.
  • The last three reported values for Assets were $881.1 million (Q4 2025), $874.7 million (Q3 2025), and $875.7 million (Q2 2025) per Business Quant data.